We are IQVIA, The Human Data Science Company
Healthcare is an industry designed to help humans. As a global community, we continuously invest and commit to advancing human health. To deliver value and real outcomes. To rise to the challenge to find the next breakthrough by making the most of increasingly limited resources
We are inspired by the potential and propelled by the possibilities. We share the vision to drive healthcare forward. To see how we can help accelerate progress and achievements. Others are developing these medical breakthroughs. We do our part by using breakthroughs in insights, technology and human intelligence to reimagine and deliver ways to help make them a reality.
It’s bigger than better clinical trials. Or advances in technologies and analytics. Or faster insights. It’s about unleashing the power of human data science. And that is why IMS Health and Quintiles have come together to be IQVIA, The Human Data Science Company.
Motivated by the industry we help, we’re committed to providing solutions that enable life sciences companies to innovate with confidence, maximize opportunities, and, ultimately, drive human health outcomes forward.
Driving Healthcare Performance in Malaysia
Established in the 1980s, IQVIA Malaysia has one of the most comprehensive offering portfolios in the region. We offer a full spectrum of clinical and commercial solutions for biopharmaceutical, medical device and other healthcare clients.
We have a strong history of innovation to meet client needs. Two of our 11 Prime Sites in Asia Pacific are in Malaysia. Prime Sites are major leading institutions with access to large numbers of patients and broad therapeutic expertise.
In 2014 we introduced the Malaysia Distributors Pharmaceutical Index (MDPI) to provide monthly market performance monitoring; in 2013 Malaysia MOH collaborated with our company to collate all the MOH Pharmaceutical procurement data, enabling IQVIA to launch the of Malaysia institute and Government Hospital Report (MiGHT).
Some of our other commercial solutions include the Malaysia Pharmaceutical Audit with postcode level data and the Malaysia Government Report, a consolidated view of the overall biopharmaceutical market.
Malaysia’s healthcare infrastructure continues to evolve. The government is promoting disease prevention and healthier living; it is improving healthcare access to address the rapidly growing incidence of chronic non-communicable diseases. Expansion of the private hospital sector, helped by liberalization of foreign investment and encouragement of medical tourism and the medical travel industry, presents further growth opportunity.
Government cost-containment measures include promotion of generics, the closer monitoring of drug prices, and changes to the pricing system, as well as a proposed pharmacoeconomic evaluation for listing on the Ministry of Health Formulary.
Supported by the world's largest and most diverse set of healthcare information with global breadth and granular depth of actionable insights, IQVIA Malaysia offers the following solutions:
IQVIA has two decades of clinical research experience in Malaysia. We have the resources, experience and site relationships necessary to help our clients' conduct clinical research in Malaysia to global standards. We have strong relationships with Malaysia's top hospitals and leading clinical research institutions. This enables faster study start-up and rapid patient recruitment. Our operations teams in Malaysia are seamlessly connected to our company's global infrastructure and leading experts across the global.
Our extensive experience enhances our ability to identify and resolve study issues before they become problems. This experience is especially important during start-up, when inexperience can cause costly delays. Our solid relationships with leading sites and investigators enable us to collect high-quality data quickly and conduct trials in Malaysia to global standards.
- Commercial effectiveness services: including sales analytics, optimization & compensation.
- Primary Intelligence throughout lifecycle of products
- Marketing Insights including Launch Excellence, Adoption Analysis multi-channel optimization, market opportunity analysis and penetration strategies.